2962 T3D2920 Flupenthixol Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. 2709-56-0 25137855 C23H27F3N2OS 434.163970 White powder. 0.000346 mg/ml Fairly slow and incomplete after oral administration Flupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS. Mainly hepatic Half Life: 19 to 39 hours LD50: 300 mk/kg (Oral,Mouse) (A308) LD50: 791 mg/kg (Oral, Rat) (A308) LD50: 87 mk/kg (Intravenous, Mouse) (A308) LD50: 37 mg/kg (Intravenous, Rat) (A308) No indication of carcinogenicity to humans (not listed by IARC). For use in the treatment of schizophrenia and depression 2009-07-21T20:27:52Z 2026-04-05T16:05:42Z Flupenthixol C11191 5121 Flupenthixol DB00875 true [H]\C(CCN1CCN(CCO)CC1)=C1\C2C=C(C=CC2SC2=CC=CC=C12)C(F)(F)F C23H27F3N2OS InChI=1S/C23H27F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,20,22,29H,3,9-15H2/b18-5- DTTVNHWDONBIKE-DVZOWYKESA-N 436.54 436.17961916 Exogenous Solid 4.51 HMDB15013 CHEMBL54661 16115 <p>Smith Kline &amp; French Laboratories; British Patent 925,538; May 8, 1963.<br /> Craig, P.N. and Zirkle, C.L.; U.S. Patent 3,282,930; November 1, 1966; assigned to Smith Kline &amp; French Laboratories.</p> CHEM002294 DTXSID3058749 NS00076284 2-(4-{3-[(9E)-2-(trifluoromethyl)-9,9a-dihydro-4aH-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol